Patterns of Brain Injury in Inborn Errors of Metabolism

Seminars in Pediatric Neurology

Volumn 19, Issue 4, 2012, Pages 203-210

  Gropman, Andrea L ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BIOLOGICAL MARKER; CREATINE; CREATINE PHOSPHATE; GLUTAMATE AMMONIA LIGASE; GLUTAMINE; INOSITOL; METHIONINE SULFOXIMINE; ORNITHINE;

ANATOMICAL VARIATION; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BLOOD BRAIN BARRIER; BRAIN INJURY; DIET; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE EXACERBATION; ELECTROENCEPHALOGRAM; GLUTARIC ACIDEMIA TYPE 1; HUMAN; IMAGE ANALYSIS; INBORN ERROR OF METABOLISM; MAPLE SYRUP URINE DISEASE; MEMBRANE PERMEABILITY; METHYLMALONIC ACIDEMIA; NERVE CELL DEGENERATION; NEUROIMAGING; NONHUMAN; NUTRITION; OXIDATIVE STRESS; PHENYLKETONURIA; PROPIONIC ACIDEMIA; UREA CYCLE DISORDER;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; BRAIN DISEASES, METABOLIC, INBORN; CREATINE; HUMANS; NEUROIMAGING; OXIDATIVE STRESS; UREA CYCLE DISORDERS, INBORN;

EID: 84870893761     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2012.09.007     Document Type: Article

References (48)

1. Saudubray J.M., Sedel F., Walter J.H. Clinical approach to treatable inborn metabolic diseases: An introduction. J Inherit Metab Dis 2006, 29:261-274.
2. Banerjee S., Bhat M.A. Neuron-glial interactions in blood-brain barrier formation. Annu Rev Neurosci 2007, 30:235-258.
3. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7:41-53.
4. Brusilow S.W., Maestri N.E. Urea cycle disorders: Diagnosis, pathophysiology, and therapy. Adv Pediatr 1996, 43:127-170.
5. Batshaw M.L., Monahan P.S. Treatment of urea cycle disorders. Enzyme 1987, 38:242-250.
6. Msall M., Batshaw M.L., Suss R., et al. Neurologic outcome in children with inborn errors of urea synthesis.Outcome of urea-cycle enzymopathies. N Engl J Med 1984, 310:1500-1505.
7. Batshaw M.L., Msall M., Beaudet A.L., et al. Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr 1986, 108:236-241.
8. Maestri N.E., Lord C., Glynn M., et al. The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency. Medicine (Baltimore) 1998, 77:389-397.
9. Gyato K., Wray J., Huang Z.J., et al. Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Ann Neurol 2004, 55:80-86.
10. Norenberg M.D. Astrocytic-ammonia interactions in hepatic encephalopathy. Semin Liver Dis 1996, 16:245-253.
11. Takahashi H., Koehler R.C., Brusilow S.W., et al. Inhibition of brain glutamine accumulation prevents cerebral edema in hyperammonemic rats. Am J Physiol 1991, 261:H825-829.
12. Seminara J., Tuchman M., Krivitzky L., et al. Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Mol Genet Metab 2010, 100(suppl 1):S97-105.
13. Gropman A.L., Fricke S.T., Seltzer R.R., et al. 1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency. Mol Genet Metab 2008, 95:21-30.
14. Morton D.H., Strauss K.A., Robinson D.L., et al. Diagnosis and treatment of maple syrup disease: A study of 36 patients. Pediatrics 2002, 109(6):999-1008.
15. Riviello J.J., Rezvani I., DiGeorge A.M., et al. Cerebral edema causing death in children with maple syrup urine disease. J Pediatr 1991, 119:42-45.
16. Schonberger S., Schweiger B., Schwahn B., et al. Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. Mol Genet Metab 2004, 82:69-75.
17. Zinnanti W.J., Lazovic J. Interrupting the mechanisms of brain injury in a model of maple syrup urine disease encephalopathy. J Inherit Metab Dis 2012, 35:71-79.
18. Sutter R., Killer H.E., Bilz S., et al. Cerebral edema and intracranial hypertension in an adult with maple syrup urine disease. Eur J Neurol 2009, 16:e45-46.
19. Ferraz-Filho J.R., Floriano V.H., Quirici M.B., et al. Contribution of the diffusion-weighted MRI in the diagnosis and follow-up of encephalopathy caused by maple syrup urine disease in a full-term newborn. Arq Neuropsiquiatr 2009, 67:719-723.
20. Jan W., Zimmerman R.A., Wang Z.J., et al. MR diffusion imaging and MR spectroscopy of maple syrup urine disease during acute metabolic decompensation. Neuroradiology 2003, 45:393-399.
21. Felber S.R., Sperl W., Chemelli A., et al. Maple syrup urine disease: Metabolic decompensation monitored by proton magnetic resonance imaging and spectroscopy. Ann Neurol 1993, 33:396-401.
22. Funchal C., Gottfried C., De Almeida L.M., et al. Evidence that the branched-chain alpha-keto acids accumulating in maple syrup urine disease induce morphological alterations and death in cultured astrocytes from rat cerebral cortex. Glia 2004, 48:230-240.
23. Brismar J., Ozand P.T. CT and MR of the brain in glutaric acidemia type I: A review of 59 published cases and a report of 5 new patients. American Journal of Neuroradiology 1995, 16:675-683.
24. Twomey E.L., Naughten E.R., Donoghue V.B., et al. Neuroimaging findings in glutaric aciduria type 1. Pediatr Radiol 2003, 33:823-830.
25. Eastwood J.D., Lev M.H., Wintermark M., et al. Correlation of early dynamic CT perfusion imaging with whole-brain MR diffusion and perfusion imaging in acute hemispheric stroke. AJNR Am J Neuroradiol 2003, 24:1869-1875.
26. Rosa R.B., Schwarzbold C., Dalcin K.B., et al. Evidence that 3-hydroxyglutaric acid interacts with NMDA receptors in synaptic plasma membranes from cerebral cortex of young rats. Neurochem Int 2004, 45:1087-1094.
27. Wolf B., Hsia Y.E., Sweetman L., et al. Propionic acidemia: A clinical update. J Pediatr 1981, 99:835-846.
28. Nyhan W.L., Bay C., Beyer E.W., et al. Neurologic nonmetabolic presentation of propionic acidemia. Arch Neurol 1999, 56:1143-1147.
29. Childs B., Nyhan W.L., Borden M., et al. Idiopathic hyperglycinemia and hyperglycinuria: A new disorder of amino acid metabolism I. Pediatrics 1961, 27:522-538.
30. Matern D., Seydewitz H.H., Lehnert W., et al. Primary treatment of propionic acidemia complicated by acute thiamine deficiency. J Pediatr 1996, 129:758-760.
31. Wolf B., Hsia Y.E., Sweetman L., et al. Propionic acidemia: A clinical update. J.Pediatr 1981, 99:835-846.
32. Surtees R.A., Matthews E.E., Leonard J.V. Neurologic outcome of propionic acidemia. Pediatr.Neurol 1992, 8:333-337.
33. North K.N., Korson M.S., Gopal Y.R., et al. Neonatal-onset propionic acidemia: Neurologic and developmental profiles, and implications for management. J.Pediatr 1995, 126:916-922.
34. Brismar J., Ozand P.T. CT and MR of the brain in disorders of the propionate and methylmalonate metabolism. AJNR 1994, 15:1459-1473.
35. Chemelli A.P., Schocke M., Sperl W., et al. Magnetic resonance spectroscopy (MRS) in five patients with treated propionic acidemia. J.Magn Reson.Imaging 2000, 11:596-600.
36. Tanpaiboon P. Methylmalonic acidemia (MMA). Mol Genet Metab 2005, 85:2-6.
37. Radmanesh A., Zaman T., Ghanaati H., et al. Methylmalonic acidemia: Brain imaging findings in 52 children and a review of the literature. Pediatr Radiol 2008, 38:1054-1061.
38. Gao Y., Guan W.Y., Wang J., et al. Fractional anisotropy for assessment of white matter tracts injury in methylmalonic acidemia. Chin Med J (Engl) 2009, 122:945-949.
39. Matalon R., Michals K. Phenylketonuria: Screening, treatment and maternal PKU. Clin Biochem 1991, 24:337-342.
40. White DA, Connor LT, Nardos B, et al: Age-related decline in the microstructural integrity of white matter in children with early- and continuously-treated PKU: A DTI study of the corpus callosum. Mol Genet Metab; 99suppl 1:S41-46, 2010.
41. Anderson PJ, Leuzzi V: White matter pathology in phenylketonuria. Mol Genet Metab; 99 suppl 1:S3-S9, 2010.
42. Ding X.Q., Fiehler J., Kohlschutter B., et al. MRI abnormalities in normal-appearing brain tissue of treated adult PKU patients. J Magn Reson Imaging 2008, 27:998-1004.
43. Braissant O, Henry H: AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: A review. J Inherit Metab Dis 2008[Epub ahead of print].
44. Braissant O., Henry H., Béard E., et al. Creatine deficiency syndromes and the importance of creatine synthesis in the brain. Amino Acids 2011, 40(5):1315-1324.
45. Cheillan D., Cognat S., Vandenberghe N., et al. Creatine deficiency syndromes. Rev Neurol (Paris) 2005, 161:284-289.
46. Renema W.K., Schmidt A., van Asten J.J., et al. MR spectroscopy of muscle and brain in guanidinoacetate methyltransferase (GAMT)-deficient mice: Validation of an animal model to study creatine deficiency. Magn Reson Med 2003, 50:936-943.
47. Chilosi A., Leuzzi V., Battini R., et al. Treatment with l-arginine improves neuropsychological disorders in a child with creatine transporter defect. Neurocase 2008, 14:151-161.
48. Schulze A., Ebinger F., Rating D., et al. Improving treatment of guanidinoacetate methyltransferase deficiency: Reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation. Mol Genet Metab 2001, 74(4):413-419.